Severe Asthma Update: Clinical Management and Key Considerations to Target Optimal Patient Care – Tweetorial #3




Patients with severe asthma suffer frequent exacerbations and unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. The utility of new therapies is underscored by the need for clinicians to be competent in making an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. The goal of this program is to ensure that clinicians are able to meet the needs of the diverse population of severe asthma patients, to design effective treatment plans that reduce symptoms and exacerbations and address the continued need for OCS in patients with severe asthma, and to recognize and treat common and rare comorbidities that present with severe asthma. Furthermore, this program will address specific considerations arising as a result of the COVID-19 pandemic and its potential detrimental impact on patients with severe asthma.


Michael S. Blaiss, MD, FACAAI
Clinical Professor of Pediatrics
Medical College of Georgia
Augusta University
Augusta, Georgia


Stanley M. Fineman, MD, MBA
Adjunct Associate Professor of Pediatrics
Emory University School of Medicine
Atlanta Allergy & Asthma
Atlanta, Georgia


David R. Stukus, MD
Associate Professor of Pediatrics
Division of Allergy & Immunology
Nationwide Children’s Hospital
Ohio State University College of Medicine
Columbus, Ohio


Release date: October 30, 2020
Expiration date: October 30, 2021
Estimated time to complete activity: 0.25 hour(s)



This educational initiative has been designed for allergists, pulmonologists, internal medicine clinicians, and advanced practice providers involved in the management of patients with severe asthma.


Upon completion of this educational activity, participants should be able to:

  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

There are no fees for participating and receiving CME credit for this activity. During the period of October 30, 2020 through October 30, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Pharmacist/ACPE learners must check the CPE monitor for their credit within 60 days of the activity.




Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-20-102-H01-P)

This is a knowledge-based activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

For information about the ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or


Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Michael S. Blaiss, MD, FACAAI
Consulting Fees: Sanofi Regeneron

Stanley M. Fineman, MD, MBA
Consulting Fees: Aimmune, Biocryst, DBV Technologies, and Regeneron
Speakers’ Bureaus: Takeda

David Stukus, MD
Consulting Fees: Abbott Nutrition, Before Brands, and DBV Technologies

The Integrity Continuing Education, Inc. planners/managers and the Global Education Group planners/managers, Ashley Marostica, RN, MSN, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


This CME activity is provided by Integrity Continuing Education, Inc.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Continue to Pretest